References
- 1. WITKOUSCA M., SMOLEWSKI P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators of Inflammation. 2013; 2013:523170.
- 2. CORREA P., PIAZUELO B.M. Helicobacter pylori infection and gastric adenocarcinoma. Gastroenterol Hepatol Rev. 2011; 7(1): 59-64.
- 3. CORREA P. Human gastric carcinogenesis: a multistep and multifactorial process first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52(24):6735-40.
- 4. VENERITO M., MALFERTHEINER P., Preneoplastic conditions in the stomach: always a point of no return? Dig Dis 2015; 33:5-10.
- 5. WONG B.C., LAM S.K., WONG W.M., CHEN J.S., ZHENG T.T., FENG R.E., et al. China gastric cancer study group: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291: 187-194.
- 6. PATEL S.K., PRATAB C.B., JAIN A.K., GULATI K., NATH G. Diagnosis of Helicobacter pylori: What should be the gold standard? World J Gastroenterol. 2014 Sep 28; 20(36): 12847-59.
- 7. http://www.gastropanel.com/ Accessed 28 November 2015.
- 8. NOAH D., ASSOUMOU M.C., BAGNAKA S.A., NGABA G.P., ALONGE I.E., PALOHEIMO L., NJOYA O., Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and Helicobacter pylori infection. Open Journal of Gastroenterology, 2012; 2:113-118.
- 9. STORKRUBB T., ARO P., RONKRAINEN J., SIPPONEN P., NYHLIN H., TALLEY NJ., et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol. 2008; 43:1448-55.
- 10. LOMBARDO L., LETO R., MOLINARO G., MIGLIARDI M., RAVARINO N., ROCCAR., TORCHIO B. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med. 2010; 48(9):1327-32.
- 11. IIJIMA K., ABE Y., KIKUCHI R., KOIKE T.I., OHARA S., SIPPONEN P., et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol. 2009; 15(7): 853-859.
- 12. LIN J.S. Screening of gastric cancer: Who, when, and how. Clinical Gastroenterology and Hepatology 2014; 12:135-138.
- 13. TERASAWA T., NISHIDA H., KATO K., MIYASHIRO I., YOSHIKAWA T., TAKAKU R., et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in eastern Asians: A systematic review and metaanalysis. PLoS One. 2014; 9(10): e109783.
- 14. CHOI H.S., LEE S-Y., KIM J.H., SUNG I-K., PARK H.S., SHIM C.S., et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. Journal of Digestive Diseases 2014; 15:293-8.
- 15. TU H., SUN L., DONG X., GONG Y., XU O., JING J., et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: A longitudinal study. Int J Cancer. 2015; 136(2):425-34.
- 16. YEH J.M., HUR C., WARD Z., SCHRAG D., GOLDIE S.J. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: A cost-effectiveness analysis. Gut 2016; 65(4):563-74.
- 17. KIM B.C., JUNG S.W., KIM J.B., HAN A.R., JANG S., PARK S.H., et al. Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth? Turk J Gastroenterol 2014; 25: 611-8.